DOCSLIB.ORG

Regulations Governing the Classification of Medical Devices (Draft)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulations Governing the Classification of Medical Devices (Draft) Regulations Governing the Classification of Medical Devices (Draft) Article 1 These Regulations are enacted pursuant to Paragraph 2, Article 3 of the Medical Devices Act (hereinafter “this Act”). Article 2 Medical devices are classified into the following categories according to their function, intended use, operating instructions, and working principle, depending on the applicable medical specialty: 1. Clinical chemistry and clinical toxicology devices 2. Hematology and pathology devices 3. Immunology and microbiology devices 4. Anesthesiology devices 5. Cardiovascular devices 6. Dental devices 7. Ear, nose, and throat devices 8. Gastroenterology and urology devices 9. General and plastic surgery devices 10. General hospital and personal use devices 11. Neurological devices 12. Obstetrical and gynecological devices 13. Ophthalmic devices 14. Orthopedic devices 15. Physical medicine devices 16. Radiology devices Article 3 Medical devices are classified into the following classes according to their risk level: 1. Class I: Low risk 2. Class II: Medium risk 3. Class III: High risk 1 Article 4 Product items of the medical device classification are specified in the Annex. In addition to rules stated in the Annex, medical devices whose function, intended use, or working principle are special may have their classification determined according to the following rules: 1. If two or more categories, classes, or product items are applicable to the same medical device, the highest class of risk level is assigned. 2. The accessory to a medical device, intended specifically by the manufacturer for use with a particular medical device, is classified the same as the particular medical device, unless otherwise specified in the Annex. 3. The classification of a combined product, which contains two or more medical devices packaged together while having two or more categories, classes, or product items applicable, is assigned the highest class of risk level among these devices. 4. A medical device containing medicine while having the primary mode of action of a medical device is determined to be a Class III medical device, unless otherwise specified in the Annex. Article 5 Medical device firms or the public may make an inquiry to the central competent authority regarding classification of medical devices or other relevant matters. Inquirers of the preceding paragraph shall fill out an inquiry form, provide the following related documents and information, and pay the required fees for submission to the central competent authority: 1. Instructions for use of the manufacturer: including operating instructions, function, and working principle. If they are not in the traditional Chinese or English version, a translation copy in traditional Chinese or English shall be provided separately. 2. Other reference information: Reference information from the United States of America, European Union, or other countries on the classification of the inquired product. If such reference information is not available, it is not required to be provided. In addition to the above documents and information, when necessary, the central competent authority may request the inquirer to provide other relevant documents and information. 2 Article 6 If the function, intended use, or working principle of the medical device does not meet identification criteria of the product items listed in the Annex, its classification shall be determined to be a Class III medical device. However, if a similar product has received license or been listed domestically, its classification shall be determined according to the risk level of the similar product, or if a classification inquiry has been made to the central competent authority in accordance with the provisions of the preceding paragraph, it shall be determined according to the risk level as responded by the central competent authority. Article 7 These Regulations shall enter into force from the effective date of this Act. 3 Annex Classification Classification Name Class Identification Number A.0001 Phencyclidine test system 2 Phencyclidine test system is a device to measure the concentration of Phencyclidine (an anesthetic agent) or Phencyclidine analog in blood, urine, or/and stomach contents. This device is to monitor the concentration of Phencyclidine or Phencyclidine analog in diseases treatment or diagnosis. A.0002 Clinical Chemistry Electrolyte System 1 Clinical chemistry electrolyte system is intended to perform a specific function in an assay that is used for the qualitative and/or quantitative determination of electrolytes and other ions in a clinical specimen. A.1020 Acid phosphatase (total or prostatic) test 2 An acid phosphatase (total or prostatic) test system is a device intended to measure the activity of the acid system phosphatase enzyme in plasma and serum. A.1025 Adrenocorticotropic hormone (ACTH) 2 An adrenocorticotropic hormone (ACTH) test system is a device intended to measure adrenocorticotropic hormone test system in plasma and serum. ACTH measurements are used in the differential diagnosis and treatment of certain disorders of the adrenal glands such as Cushing's syndrome, adrenocortical insufficiency, and the ectopic ACTH syndrome. A.1030 Alanine amino transferase (ALT/SGPT) 1 An alanine amino transferase (ALT/SGPT) test system is a device intended to measure the activity of the enzyme test system alanine amino transferase (ALT) (also known as a serum glutamic pyruvic transaminase or SGPT) in serum and plasma. Alanine amino transferase measurements are used in the diagnosis and treatment of certain liver diseases (e.g., viral hepatitis and cirrhosis) and heart diseases. A.1035 Albumin test system 2 An albumin test system is a device intended to measure the albumin concentration in serum and plasma. Albumin measurements are used in the diagnosis and treatment of numerous diseases involving primarily the liver or kidneys. A.1040 Aldolase test system 1 An aldolase test system is a device intended to measure the activity of the enzyme aldolase in serum or plasma. Aldolase measurements are used in the diagnosis and treatment of the early stages of acute hepatitis and for certain muscle diseases such as progressive Duchenne-type muscular dystrophy. A.1045 Aldosterone test system 2 An aldosterone test system is a device intended to measure the hormone aldosterone in serum and urine. Aldosterone measurements are used in the diagnosis and treatment of primary aldosteronism (a disorder caused by the excessive secretion of aldosterone by the adrenal gland), hypertension caused by primary aldosteronism, selective hypoaldosteronism, edematous states, and other conditions of electrolyte imbalance. A.1050 Alkaline phosphatase or isoenzymes test 2 An alkaline phosphatase or isoenzymes test system is a device intended to measure alkaline phosphatase or its system isoenzymes (a group of enzymes with similar biological activity) in serum or plasma. Measurements of alkaline phosphatase or its isoenzymes are used in the diagnosis and treatment of liver, bone, parathyroid, and intestinal diseases. 1/222 A.1055 Newborn screening test system for amino 2 A newborn screening test system for amino acids, free carnitine, and acylcarnitines using tandem mass acids, free carnitine, and acylcarnitines spectrometry is a device that consists of stable isotope internal standards, control materials, extraction solutions, using tandem mass spectrometry. flow solvents, instrumentation, software packages, and other reagents and materials. The device is intended for the measurement and evaluation of amino acids, free carnitine, and acylcarnitine concentrations from newborn whole blood filter paper samples. The quantitative analysis of amino acids, free carnitine, and acylcarnitines and their relationship with each other provides analyte concentration profiles that may aid in screening newborns for one or more inborn errors of amino acid, free carnitine, and acyl-carnitine metabolism. A.1060 Delta-aminolevulinic acid test system 1 Adelta -aminolevulinic acid test system is a device intended to measure the level ofdelta -aminolevulinic acid (a precursor of porphyrin) in urine.Delta -aminolevulinic acid measurements are used in the diagnosis and treatment of lead poisoning and certain porphyrias (diseases affecting the liver, gastrointestinal, and nervous systems that are accompanied by increased urinary excretion of various heme compounds includingdelta -aminolevulinic acid). A.1065 Ammonia test system 1 An ammonia test system is a device intended to measure ammonia levels in blood, serum, and plasma, Ammonia measurements are used in the diagnosis and treatment of severe liver disorders, such as cirrhosis, hepatitis, and Reye's syndrome. A.1070 Amylase test system 2 An amylase test system is a device intended to measure the activity of the enzyme amylase in serum and urine. Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis (inflammation of the pancreas). A.1075 Androstenedione test system 1 An androstenedione test system is a device intended to measure androstenedione (a substance secreted by the testes, ovary, and adrenal glands) in serum. Adrostenedione measurements are used in the diagnosis and treatment of females with excessive levels of androgen (male sex hormone) production. A.1080 Androsterone test system 1 An androsterone test system is a device intended to measure the hormone adrosterone in serum, plasma, and urine. Androsterone measurements are used in the diagnosis and treatment of gonadal and
Load more

Recommended publications
  • Review of Plastic Surgery Biomaterials and Current Progress in Their 3D Manufacturing Technology
    materials Review Review of Plastic Surgery Biomaterials and Current Progress in Their 3D Manufacturing Technology 1,2, 3, 4 5 5 4 Wei Peng y, Zhiyu Peng y , Pei Tang , Huan Sun , Haoyuan Lei , Zhengyong Li , Didi Hui 6 , Colin Du 6, Changchun Zhou 5 and Yongwei Wang 1,2,* 1 Department of Palliative Care, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu 610041, China; [email protected] 2 Occupational Health Emergency Key Laboratory of West China Fourth Hospital, Sichuan University, Chengdu 610041, China 3 Department of Thoracic Surgery, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China; [email protected] 4 Department of Burn and Plastic Surgery, West China School of Medicine, West China Hospital, Sichuan University, Chengdu 610041, China; [email protected] (P.T.); [email protected] (Z.L.) 5 National Engineering Research Center for Biomaterials, Sichuan University, Chengdu 610064, China; [email protected] (H.S.); [email protected] (H.L.); [email protected] (C.Z.) 6 Innovatus Oral Cosmetic & Surgical Institute, Norman, OK 73069, USA; [email protected] (D.H.); [email protected] (C.D.) * Correspondence: [email protected] These authors contributed equally to this paper. y Received: 18 August 2020; Accepted: 14 September 2020; Published: 16 September 2020 Abstract: Plastic surgery is a broad field, including maxillofacial surgery, skin flaps and grafts, liposuction and body contouring, breast surgery, and facial cosmetic procedures. Due to the requirements of plastic surgery for the biological safety of materials, biomaterials are widely used because of its superior biocompatibility and biodegradability.
    [Show full text]
  • The Developmental Genetics of Hemoglobin Synthesis in Chironomus Darrel Starr English Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1968 The developmental genetics of hemoglobin synthesis in Chironomus Darrel Starr English Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Genetics Commons Recommended Citation English, Darrel Starr, "The developmental genetics of hemoglobin synthesis in Chironomus " (1968). Retrospective Theses and Dissertations. 3660. https://lib.dr.iastate.edu/rtd/3660 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. This dissertation has been microfilmed exactly as received 6 8-14,785 ENGLISH, Barrel Starr, 1936- THE DEVELOPMENTAL GENETICS OF HEMOGLOBIN SYNTHESIS IN CHIRONOMUS. Iowa State University, Ph.D., 1968 Biology- Genetics University Microfilms, Inc., Ann Arbor, Michigan THE DEVELOPMENTAL GENETICS OF HEMOGLOBIN SYNTHESIS IN CHIRONOMUS by Darrel Starr English A Dissertation Submitted to the Graduate Faculty in Partial Fulfillment of The Requirements for the Degree of DOCTOR OF PHILOSOPHY Major Subject: Genetics Approved: Signature was redacted for privacy. In Charge of MajdA Work Signature was redacted for privacy. Head ^ Major Department Signature was redacted for privacy.
    [Show full text]
  • Braun-Products.Pdf
    Braun products. In depth Table of contents. Core categories Male power grooming Female hair removal Hair care Licensed Oral Care Household with De’Longhi SpA Clocks and watches with Zeon Ltd. Health & Wellness with KAZ Inc. History Lighters & flashlights Photography & film Thermometers & blood pressure monitors Entertainment electronics Clocks and watches Household Core categories. Back to contents 4 Core category products Braun in depth Back to contents Core categories. Male power grooming Female hair removal Hair care appliances Electric shavers, Silk-épil epilators, lady shavers, Dryers, curlers, brush, beard and hair trimmers bikini styler and IPL hair removal straighteners and airstylers Back to contents Download images Male power grooming. 2 6 0.35 mm …is what human hair grows every day The S 50 (1), whose shaving foil manufacture represented a pioneering 1 achievement of precision engineering, marked the launch in 1950 of this prod- uct line, that has remained very successful up to the present day. The sixtant in the 1960s (2) was the first mass-produced article of the Braun design era to be brought onto the market. Since the 1970s, shavers have represented the company’s core business. The success of this division is due among other 3 reasons to the continuous sequence of innovations that Braun has introduced. A good example of this is shaving head optimization: in 1990, Braun intro- duced the Flex control (3), the first shaver on the market with two shaving foils and a pivoting head. The Flex integral in 1994 (4) featured an integrated hair trimmer to help shave longer hairs or hairs that grew sideways.
    [Show full text]
  • A Distant Gene Deletion Affects Beta-Globin Gene Function in an Atypical Gamma Delta Beta-Thalassemia
    A distant gene deletion affects beta-globin gene function in an atypical gamma delta beta-thalassemia. P Curtin, … , A D Stephens, H Lehmann J Clin Invest. 1985;76(4):1554-1558. https://doi.org/10.1172/JCI112136. Research Article We describe an English family with an atypical gamma delta beta-thalassemia syndrome. Heterozygosity results in a beta-thalassemia phenotype with normal hemoglobin A2. However, unlike previously described cases, no history of neonatal hemolytic anemia requiring blood transfusion was obtained. Gene mapping showed a deletion that extended from the third exon of the G gamma-globin gene upstream for approximately 100 kilobases (kb). The A gamma-globin, psi beta-, delta-, and beta-globin genes in cis remained intact. The malfunction of the beta-globin gene on a chromosome in which the deletion is located 25 kb away suggests that chromatin structure and conformation are important for globin gene expression. Find the latest version: https://jci.me/112136/pdf A Distant Gene Deletion Affects ,8-Globin Gene Function in an Atypical '6y5-Thalassemia Peter Curtin, Mario Pirastu, and Yuet Wai Kan Howard Hughes Medical Institute and Department ofMedicine, University of California, San Francisco, California 94143 John Anderson Gobert-Jones Department ofPathology, West Suffolk County Hospital, Bury St. Edmunds IP33-2QZ, Suffolk, England Adrian David Stephens Department ofHaematology, St. Bartholomew's Hospital, London ECIA-7BE, England Herman Lehmann Department ofBiochemistry, University ofCambridge, Cambridge CB2-lQW, England Abstract tologic picture of f3-thalassemia minor in adult life. Globin syn- thetic studies reveal a ,3 to a ratio of -0.5, but unlike the usual We describe an English family with an atypical 'yS6-thalassemia fl-thalassemia heterozygote, the levels of HbA2 (and HbF) are syndrome.
    [Show full text]
  • 8.5 X12.5 Doublelines.P65
    Cambridge University Press 978-0-521-87519-6 - Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Second Edition Edited by Martin H. Steinberg, Bernard G. Forget, Douglas R. Higgs and David J. Weatherall Index More information anti-inflammatory therapy, 762–763 thalassemia-related complications, 779 sulfasalazine, nuclear factor (NF)-kB, 762 transplant-related complications, 778–779 targeting ET-1, 762–763 ␤S-linked haplotypes, African/Indo-European, anti-oxidant therapy targeting erythrocyte, 638–640 765–766 burst forming unit-erythroid (BFU-E), 10, 29 deferiprone, 765 oral glutamine, 765 calcium-activated potassium channel (Gardos oral N-acetyl-cysteine, 765–766 pathway), 167–168 anti-oxidant therapy targeting vascular, 763–765 capillary electrophoresis, 660 Index Apo A-I mimetics, 764 capillary IEF, 660 NO, 763–764 carbon monoxide poisoning, 613–616 statins, 764 clinical features, 615 xanthine oxidase inhibitors, 764–765 diagnosis, treatment, 615–616 anti-thrombotic therapy epidemiology, 613–614 ␤-thalassemia, 761–762 cardiac, arterial abnormalities, 151 sickle cell disease, 761–762 cardiac abnormalities, ATRX syndrome, 305 aortagonad-mesonephros (AGM), 6 cardiovascular disease, 652 Apo A-I mimetics, 764 cation content, cellular hydration, 164–172 apoptosis, vasculature permeability, 193–194 calcium-activated potassium channel, 167–168 assays, assay systems, 7, 142 cation permeability alterations, 166–167 ATMDS. See ␣ thalassemia-myelodysplastic cell calcium, calcium pump activity, 167 syndromes cell sodium,
    [Show full text]
  • OVESTIN PESSARY (0.5Mg)
    NEW ZEALAND DATA SHEET 1. OVESTIN PESSARY (0.5mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pessary contains 0.5 mg Estriol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Pessary 0.5 mg - white, torpedo formed pessary. One pessary (2.5 g weight) contains 0.5 mg oestriol. Length 26.5 mm; largest diameter 14 mm. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Atrophy of the lower urogenital tract related to oestrogen deficiency, notably • for the treatment of vaginal complaints such as dyspareunia, dryness and itching. • for the prevention of recurrent infections of the vagina and lower urinary tract. • in the management of micturition complaints (such as frequency and dysuria) and mild urinary incontinence. Pre- and postoperative therapy in postmenopausal women undergoing vaginal surgery. A diagnostic aid in case of a doubtful atrophic cervical smear. 4.2 Dose and method of administration Dosage OVESTIN is an oestrogen-only product that may be given to women with or without a uterus. Atrophy of the lower urogenital tract 1 pessary per day for the first weeks, followed by a gradual reduction, based on relief of symptoms, until a maintenance dosage (e.g. 1 pessary twice a week) is reached. Pre- and post-operative therapy in postmenopausal women undergoing vaginal surgery 1 pessary per day in the 2 weeks before surgery; 1 pessary twice a week in the 2 weeks after surgery. A diagnostic aid in case of a doubtful atrophic cervical smear 1 pessary on alternate days in the week before taking the next smear. Administration OVESTIN pessaries should be inserted intravaginally before retiring at night.
    [Show full text]
  • UK Clinical Guideline for Best Practice in the Use of Vaginal Pessaries for Pelvic Organ Prolapse
    UK Clinical Guideline for best practice in the use of vaginal pessaries for pelvic organ prolapse March 2021 Developed by members of the UK Clinical Guideline Group for the use of pessaries in vaginal prolapse representing: the United Kingdom Continence Society (UKCS); the Pelvic Obstetric and Gynaecological Physiotherapy (POGP); the British Society of Urogynaecology (BSUG); the Association for Continence Advice (ACA); the Scottish Pelvic Floor Network (SPFN); The Pelvic Floor Society (TPFS); the Royal College of Obstetricians and Gynaecologists (RCOG); the Royal College of Nursing (RCN); and pessary users. Funded by grants awarded by UKCS and the Chartered Society of Physiotherapy (CSP). This guideline was completed in December 2020, and following stakeholder review, has been given official endorsement and approval by: • British Association of Urological Nurses (BAUN) • International Urogynecological Association (IUGA) • Pelvic Obstetric and Gynaecological Physiotherapy (POGP) • Scottish Pelvic Floor Network (SPFN) • The Association of Continence Advice (ACA) • The British Society of Urogynaecology (BSUG) • The Pelvic Floor Society (TPFS) • The Royal College of Nursing (RCN) • The Royal College of Obstetricians and Gynaecologists (RCOG) • The United Kingdom Continence Society (UKCS) Review This guideline will be due for full review in 2024. All comments received on the POGP and UKCS websites or submitted here: [email protected] will be included in the review process. 2 Table of Contents Table of Contents ................................................................................................................................
    [Show full text]
  • Pessary for Management of Pelvic Organ Prolapse
    Pessary for management of Pelvic Organ Prolapse Cathy Davis Clinical Nurse Specialist Department of Urogynaecology King’s College Hospital, London Definition of Prolapse The descent of one or more of the anterior vaginal wall, posterior vaginal wall, uterus (cervix) or vaginal vault (cuff scar after hysterectomy). The presence of any such sign should be correlated with relevant POP symptoms. (Haylen et al 2016) Risk Factors • Increased intra-abdominal pressure • Chronic cough • Chronic constipation • Weight lifting • Presence of abdominal tumours - fibroids & ovarian cysts • High impact exercise • Age/ Menopause • Obesity Risk Factors contd.... • Smoking • Multiparity • Congenital weakness – rare; due to deficiency in collagen metabolism • Injury to pelvic floor muscles • Iatrogenic/ pelvic surgery - hysterectomy Symptoms of POP • May be asymptomatic – a small amount of prolapse can often be normal • Sensation of a lump or bulge " coming down" - most common • Backache • Heaviness • Dragging or discomfort inside the vagina – often worse on standing /sitting for prolonged periods • Seeing a lump or bulge Symptoms of POP contd.... • Bladder / Urinary symptoms -Frequency -Difficulty initiating voids, low-flow, incomplete bladder emptying -Leakage on certain movements or when lifting heavy objects -Recurrent urinary tract infections • Bowel symptoms -Constipation - Incomplete bowel emptying - May have to digitate to defecate/use aides • Symptoms related to Sex – uncomfortable, lack of sensation Diagnosis of Prolapse • Vaginal examination •
    [Show full text]
  • Combi Soft Gel Pessary & External Cream
    Combi Soft Gel Pessary Canesten & External Cream 500mg vaginal capsule & 2% w/w cream Clotrimazole Read all of this leaflet carefully because it contains important To treat internal thrush, your doctor may recommend that you use the information for you. pessary without the help of an applicator. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. HOW TO USE CANESTEN® COMBI • This medicine has been prescribed for you. Do not give it to anyone else 3. under any circumstances. The Soft Gel Pessary: • If you have any unusual effects after using this product, tell your doctor. Unless directed otherwise by your doctor, the Soft Gel Pessary should be inserted as high as possible into the vagina, preferably before going to sleep IN THIS LEAFLET at night for convenient and comfortable treatment. Wash your hands before removing the foil from the blister pack and again 1. What is Canesten Combi and what is it used for? afterwards when you have used the applicator. 2. Before you use Canesten Combi 3. How to use Canesten Combi 1. Remove the applicator from the packaging. Pull out the plunger A until it 4. Possible side effects stops. Remove the pessary from the foil blister pack and place firmly into the 5. How to store Canesten Combi applicator B. 6. Further information 1. WHAT IS CANESTEN® COMBI AND WHAT IS IT USED FOR? Canesten Combi Soft Gel Pessary & External Cream is a full course of treatment for vaginal thrush (candidiasis) because it treats both the internal cause and external symptoms.
    [Show full text]
  • Complementing Surgical with Biomedical and Engineering Methods to Evolve Lip and Nose Reconstruction
    Complementing surgical with biomedical and engineering methods to evolve lip and nose reconstruction Inauguraldissertation zur Erlangung der Würde eines Doktors der Philosophie vorgelegt der Medizinischen Fakultät der Universität Basel von Andreas Albert Müller aus Basel (Basel-Stadt), Oftringen (Aargau), Schweiz Basel, 2013 Genehmigt von der Medizinischen Fakultät auf Antrag von Prof. Dr. Dr. Dr.h.c. Hans-Florian Zeilhofer (Fakultätsverantwortlicher und Korreferent) Prof. Dr. Ivan Martin (Dissertationsleiter) Prof. em. Dr. Dr. Dieter Schumann (externer Experte) Basel, den 16. September 2013 Prof. Dr. Christoph Beglinger Dekan der Medizinischen Fakultät Contents Abstract ...................................................................................................................................... 1 1. Introduction ........................................................................................................................... 3 Shape reconstruction of central facial defects ...................................................................... 3 Current standards of microsurgical tissue transfer to the face ............................................. 4 Introducing the functional vascular anatomy to cleft lip surgery .......................................... 4 Combined cleft lip and palate repair to reduce the burden of care ...................................... 5 Umbilical cord stem cells to heal inborn bone defects .......................................................... 5 2. First study: Missing facial parts computed
    [Show full text]
  • UNIVERSITY of CALIFORNIA, SAN DIEGO Design and Manufacturing
    UNIVERSITY OF CALIFORNIA, SAN DIEGO Design and manufacturing of a disposable endoscope and an overtube using 3-D printing technology A thesis submitted in partial satisfaction of the requirements for the degree Master of Science in Engineering Sciences (Mechanical Engineering) by Anay Mahesh Pandit Committee in Charge: Frank E. Talke, Chair Vlado Lubarda Mike Tolley 2017 Copyright Anay Mahesh Pandit, 2017 All rights reserved. The thesis of Anay Mahesh Pandit is approved, and it is acceptable in quality and form for publication on micro film and electronically: ______________________________________________________________ ______________________________________________________________ ______________________________________________________________ Chair University of California, San Diego 2017 iii DEDICATION To my parents, Mahesh Pandit and Sucheta Pandit iv TABLE OF CONTENTS Signature page ................................................................................................................................. iii Dedication ....................................................................................................................................... iv Table of contents .............................................................................................................................. v List of figures ................................................................................................................................. vii List of tables ....................................................................................................................................
    [Show full text]
  • Nano-Silver Products Inventory
    Petition Appendix A: Nano-Silver Products Inventory Compiled by Center for Food Safety Country of PRODUCT TYPE OF PRODUCT COMPANY WEBSITE Marketing Claim Origin http://www.sourcenaturals.com/products/GP1 Wellness Colloidal Silver™ is produced using a unique electrical process Wellness Colloidal Silver™ Nasal 490 which creates homogeneity, minute particle size, and stability of the Spray Personal Care Source Naturals USA silver particles. http://ciko8.en.ec21.com/Vegetable_Fruits_Cle Removing pesticide residues completely from the fruit and vegetables. aner--1059718_1059768.html Powered by four electric oscillators. Nano-silver/Ozone-Extermination Germs. Washing and sterilizing dishes. No more bacteria such as colon bacillus, salmonella and O-157. Defrosting frozen meat or fish in 5 Vegetable & Fruits Cleaner Cooking 3EVER Co. Ltd Korea minutes. http://www.e- NINK®-Ag series, conductive silver ink series of ABC NANOTECH, are djtrade.com/co/abcnano/GC01567926/CA0156 devised for convenient use of piezoelectricinkjet printing on the various 8109/NINK_Ag_(Silver_Conductive_Ink substrates. NINK®-Ag series aremade up of surface modified nano-silver which is developedby a unique technology of ABC NANOTECH. Fine-pitch conductive lines can be demonstrated on the various plates, such as olycarbonate, polyester, polyimide, and ceramics, by using NINK®-Ag series. Nano-sized silver particles can be sintered at lower temperatures, around 150°C, than microsized silver particles can. NINK®-Ag series are applied to conductive line formation in the shorter process than existing conductive line formation methods." .html) NINK®-Ag Silver Conductive Ink Computer Hardware ABC NanoTech Co, Ltd. Korea http://www.evelinecharles.com/product_detail Nano Silver Cleanser is not a soap, it's a revolution.
    [Show full text]